Dronabinol

Generic Name: Dronabinol

Brand Names: Marinol, Sativex, Syndros

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 1972-08-3

Unique Ingredient Identifier: 7J8897W37S

Background: Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...

Indication: Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions: Anorexia, Chemotherapy-Induced Nausea and Vomiting

Associated Therapies: -

Clinical Trials

A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2013-03-18

Last Posted Date: 2022-12-20

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT01812616

Locations: 🇩🇪
Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Universitätsklinikum Aachen RWTH, Aachen, Germany
🇩🇪
Neurologie des Klinikums Altenburger Land, Altenburg, Germany
🇩🇪
Zentrum für Neuroonkologie der Universität Duesseldorf, Duesseldorf, Germany

and more 8 locations

Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2013-02-07

Last Posted Date: 2013-03-14

Lead Sponsor: Michael Camilleri

Target Recruit Count: 75

Registration Number: NCT01786109

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea

Phase 2

Completed

Conditions: Sleep Apnea, Obstructive

Interventions: Drug: Placebo (for Dronabinol)
Drug: Dronabinol

First Posted Date: 2012-12-21

Last Posted Date: 2021-07-29

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 75

Registration Number: NCT01755091

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

Fixed or Self-Titrated Dosages of Sativex on Cannabis Users

Not Applicable

Completed

Conditions: Cannabis Dependence

Interventions: Drug: Sativex
Drug: Placebo

First Posted Date: 2012-12-13

Last Posted Date: 2016-02-01

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 16

Registration Number: NCT01748799

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence

Phase 2

Completed

Conditions: Cannabis Dependence

Interventions: Behavioral: Motivational Enhancement/Cognitive Behavioral Therapy
Drug: Placebo spray
Drug: Sativex

First Posted Date: 2012-12-12

Last Posted Date: 2017-10-02

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 45

Registration Number: NCT01747850

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Safety and Tolerability of Namisol in the Elderly

Phase 1

Completed

Conditions: Drug Safety

Interventions: Drug: Placebo
Drug: delta-9-tetrahydrocannabinol

First Posted Date: 2012-12-04

Last Posted Date: 2014-01-07

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 12

Registration Number: NCT01740960

Locations: 🇳🇱
Radboud University Medical Centre, department of Geriatrics, Nijmegen, Gelderland, Netherlands

A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

Phase 3

Completed

Conditions: Neuropathic Pain
Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2012-05-23

Last Posted Date: 2023-01-10

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT01604265

Locations: 🇬🇧
Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom

The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain

Phase 4

Completed

Conditions: Chest Pain

Interventions: Drug: Marinol
Drug: Placebo

First Posted Date: 2012-05-15

Last Posted Date: 2017-04-28

Lead Sponsor: Yehudith Assouline-Dayan

Target Recruit Count: 13

Registration Number: NCT01598207

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

Phase 2

Terminated

Conditions: Cannabis Dependence
Marijuana Dependence

Interventions: Drug: Placebo
Drug: Dronabinol
Drug: Clonidine

First Posted Date: 2012-05-15

Last Posted Date: 2018-08-29

Lead Sponsor: Mclean Hospital

Target Recruit Count: 12

Registration Number: NCT01598896

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2012-05-15

Last Posted Date: 2023-05-03

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 337

Registration Number: NCT01599234

Locations: 🇬🇧
The Royal Berkshire and Battle Hospitals NHS Trust, Reading, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy